Retinal drugs companies focus on developing pharmaceuticals for the treatment of retinal disorders and diseases, including age-related macular degeneration and diabetic retinopathy. These companies contribute to ophthalmology by providing medications that aim to preserve and improve retinal health.
Latest Retinal Drugs Companies Update
Sobi receives EMA approval for Igalolix (pegvoribate) novel therapy offers a potentially transformative treatment for adults with moderate to severe Hemophilia A with inhibitors, providing prolonged protection against bleeding through a new mechanism of action.
BioMarin initiates Phase 3 trial for valoctocogene roxadustat A (ROX-A ViiV) gene therapy aims to provide a potential cure for Hemophilia A by addressing the underlying genetic defect, holding immense promise for long-term management of the condition.
Alnylam Pharmaceuticals announces positive Phase 3 results for lumasiran RNA interference (RNAi) therapy demonstrates efficacy in preventing bleeding episodes in Hemophilia A patients, potentially offering another innovative treatment option.
Roche acquires Tropic Biosciences acquisition strengthens Roche's hemophilia portfolio with Tropic's innovative gene therapy candidate for Hemophilia B, solidifying their position in this area.
Pfizer partners with Sanofi collaboration focuses on developing novel gene therapies for both Hemophilia A and B, combining their expertise and resources to accelerate research and development efforts.
Bayer collaborates with Spark Therapeutics partnership aims to explore potential synergies between Bayer's existing hemophilia treatments and Spark's gene therapy technologies, striving for comprehensive management solutions.
Retinal Drugs Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)